CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

83221

APPROVAL LETTER

NDA 83-221
10-156

Bolar Pharmaceutical Co. Inc.
Attention: Robert Shulman
130 Lincoln Street
Copiague, New York 11726

APR 07 1975

Gentlemen:

Reference is made to your abbreviated new drug application submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Probenecid, 500 mg. with Colchicine, 0.5 mg., Tablets.

Reference is also made to your communication dated February 7, 1975, relating to analytical procedures.

We have completed the review of this abbreviated new drug application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated new drug application, requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

This Administration should be advised of any change in the marketing status of this drug.

The requirement for adequate data to assure the biologic availability is being deferred at the present time. However, our action in approving this application is based upon an understanding that if this requirement is reinstated you will perform the appropriate procedures.

Promotion of a product marketed under an abbreviated new drug application must not convey the impression that the product is a new entity.

The enclosures summarize the conditions relating to the approval of this application.

Sincerely yours,

/S/

4/7/75

Marvin Seife, M.D.
Director
Division of Generic Drug Monographs
Office of Drug Monographs
Bureau of Drugs

cc:
HFD-530
HFD-616
HFD-614
Approval
jbacsanyi/jlmeyer/majarski

majarski 4/3/75

gbacsanyi 4-4-75

JLMeyer 4/4/75

Enclosures:
Conditions of Approval of a New Drug Application
Records and Reports Requirement